Eribulin mesylate injection Clinical Trials
3 recruitingDrug
Phase 32Phase 11Phase 21
Showing 1–3 of 3 trials
Recruiting
Phase 3
JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
Breast Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd400 enrolled87 locationsNCT06079983
Recruiting
Phase 3
Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer
Fludzoparib" and Anti-angiogenicHRD-positive/HER2-negative Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University200 enrolled1 locationNCT06255392
Recruiting
Phase 1Phase 2
A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer
Metastatic Breast CancerRecurrent Breast CancerAdvanced Malignancies
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.154 enrolled2 locationsNCT06202261